-
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience. Oncology (IF 3.5) Pub Date : 2023-11-27 Humaira Sarfraz,Shahla Bari,Junmin Whiting,Melissa Sur,Qianxing Mo,Melissa Armitage,Ricardo L B Costa
INTRODUCTION Alpelisib is approved in combination with endocrine therapy (ET) to treat patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) progressive metastatic breast cancer (MBC). The SOLAR-1 trial demonstrated the efficacy of this oral agent and showed that, while alpelisib improves outcomes compared to placebo, it is also associated with clinically
-
Co-culture device for in vitro high throughput analysis of cancer associated fibroblast and cancer cell interactions. Oncology (IF 3.5) Pub Date : 2023-11-25 Adam Germain,Young-Tae Kim
Introduction Cancers in general, and specifically lung cancer, continue to have low patient survival rates when the patient is at an advanced stage when diagnosed. It appears that the local environment, especially fibroblasts and their signaling molecules, tends to induce metastasis, increase cancer cell resistance to treatment, and aid in tumor growth rates. Since 3-D models quickly become too complex
-
IMMUNOHISTOCHEMICAL EXPRESSION OF INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) AND ITS ASSOCIATION WITH CLINICOPATHOLOGICAL PARAMETERS IN HEPATOCELLULAR CARCINOMA. Oncology (IF 3.5) Pub Date : 2023-11-21 Maria Luiza Peloso Maia,Ronniel Morais Albuquerque,Serena Dafne do Carmo Silva,Cristiano Xavier Lima,Paulo Henrique Costa Diniz,Paula Vieira Teixeira Vidgal
INTRODUCTION Hepatocellular carcinoma (HCC) carcinogenesis is not yet fully known. Insulin-like Growth Factor-1 Receptor (IGF-1R) can translocate to the nucleus and modulate cellular growth, possibly participating in HCC development and aggressiveness. This study aims to evaluate the immunoexpression of IGF-1R in HCC, the cellular compartment involved, and its association with clinicopathological parameters
-
Relative efficacies of EGFR-TKIs and immune checkpoint inhibitors for treatment of recurrent non-small cell lung cancer after surgery. Oncology (IF 3.5) Pub Date : 2023-11-20 Nozomu Motono,Takaki Mizoguchi,Masahito Ishikawa,Shun Iwai,Yoshihito Iijima,Hidetaka Uramoto
INTRODUCTION The relative efficacies of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) for the treatment of recurrent non-small cell lung cancer (NSCLC) after surgery remain unclear. METHODS Among 801 patients with NSCLC who underwent pulmonary resection at Kanazawa Medical University between 2017 and 2021, 64 patients had recurrence
-
Association between lower lobe location and early recurrence for non-small cell lung cancer. Oncology (IF 3.5) Pub Date : 2023-11-07 Nozomu Motono,Takaki Mizoguchi,Masahito Ishikawa,Shun Iwai,Yoshihito Iijima,Hidetaka Uramoto
OBJECTIVES It is unclear whether a lower lobe origin is a risk factor for early recurrence of non-small cell lung cancer (NSCLC) in patients who underwent pulmonary resection. MATERIALS AND METHODS The risk factors for early recurrence, defined as recurrence occurring within 1 year after surgery, were analyzed in 476 patients with NSCLC who underwent pulmonary resection without wedge resection. RESULTS
-
Total neoadjuvant therapy approach for the treatment of locally advanced rectal cancer. Where do we stand? Oncology (IF 3.5) Pub Date : 2023-11-07 Sigfredo Elias Romero Zoghbi,Margarita Martín Martín,Juan Carlos García,Mireia Valero,Diego Rincón,Marina Peña Huertas,Juan Pablo Fusco,Escarlata López,Juan Zafra,David Fernández Luengas,Fernando López-Campos,Felipe Couñago
BACKGROUND for the management of locally advanced rectal cancer (LARC), initial treatment with neoadjuvant chemoradiotherapy followed by surgery and chemotherapy in selected patients is considered one of the recommended options by the main international clinical guidelines. Nonetheless, the administration of all chemotherapy before definitive treatment (total neoadjuvant therapy or TNT) is an optimal
-
Clinicopathological characteristics and survival outcomes in patients with advanced esophageal squamous cell carcinoma who were intraoperatively diagnosed non-curative. Oncology (IF 3.5) Pub Date : 2023-11-03 Takahito Sugase,Takashi Kanemura,Tomohira Takeoka,Keijiro Sugimura,Masaaki Yamamoto,Naoki Shinno,Hisashi Hara,Takeshi Omori,Yosuke Mukai,Manabu Mikamori,Shinichiro Hasegawa,Naotsugu Haraguchi,Hirofumi Akita,Junichi Nishimura,Hiroshi Wada,Chu Matsuda,Masayoshi Yasui,Hiroshi Miyata
INTRODUCTION Curative esophagectomy is not always possible in patients with locally advanced esophageal cancer. However, few studies have investigated patients who underwent non-curative surgery with intraoperative judgment. This study aimed to investigate patient characteristics and clinical outcomes for patients undergoing non-curative surgery and compare them between non-resectional and non-radical
-
Is total neoadjuvant treatment beneficial for locally advanced rectal cancer? a meta-analysis of randomized controlled trials. Oncology (IF 3.5) Pub Date : 2023-11-03 Hai-Qiong Wu,Jun Li,Ji-Dong Miao,Jia-Wei Li
BACKGROUND Total neoadjuvant therapy (TNT) is a new strategy combining neoadjuvant therapy and chemotherapy to enhance tumor shrinkage and systemic control. Its effectiveness remains debated. OBJECTIVES This study conducts a meta-analysis of randomized controlled trials (RCTs) to assess TNT's impact and provide high-quality evidence for rectal cancer treatment decisions. METHOD We searched China National
-
Association between artificial sweeteners-aspartame consumption and colorectal cancer risk: evidence-based strategies. Oncology (IF 3.5) Pub Date : 2023-11-02 Chenglou Zhu,Dandan Ji,Jichun Ma,Mingxu Da
In this study, clinical trials were generalized, summarized, and meta-analyzed to evaluate correlations between artificial sweeteners (ASs) and colorectal cancer (CRC). PubMed, Web of Science, EMBASE (Ovid platform), MEDLINE, and the Cochrane Library databases were searched from inception until July 24, 2023. The association between AS exposure and CRC incidence was assessed using odds ratios (ORs)
-
Effects of Laughter Therapy on Improving Negative Emotions Associated with Cancer: A Systematic Review and Meta-Analysis. Oncology (IF 3.5) Pub Date : 2023-10-31 Hongyu Shi,Yuejin Wu,Lu Wang,Xiuling Zhou,Feng Li
INTRODUCTION With aging and growth of the population, the risk of cancer incidence and mortality is rapidly increasing. However, psychosocial treatment has been seriously neglected in many healthcare settings. Laughter therapy is a therapeutic program to improve emotional wellbeing and health which has been applied as a complementary treatment. We aim to explore effects of laughter therapy for patients
-
Comparison of efficacy and safety between carboplatin-etoposide and cisplatin-etoposide combination therapy in patients with advanced neuroendocrine carcinoma, retrospective study. Oncology (IF 3.5) Pub Date : 2023-10-30 Hiroo Imai,Ken Saijo,Yoshifumi Kawamura,Shuto Kodera,Keigo Komine,Tomoyuki Iwasaki,Noriko Takenaga,Yuki Kasahara,Kota Ouchi,Hidekazu Shirota,Masanobu Takahashi,Chikashi Ishioka
INTRODUCTION Neuroendocrine carcinoma (NEC) is characterized by a poor prognosis and is generally treated with platinum and etoposide combination therapy as first-line chemotherapy. However, it remains uncertain whether carboplatin and etoposide combination therapy (CE) and cisplatin and etoposide combination therapy (PE) have comparable treatment efficacy. In this retrospective analysis, we compared
-
Chemoradiotherapy combined with immunotherapy in stage III non-small cell lung cancer: a systematic review and meta-analysis of efficacy and safety outcomes. Oncology (IF 3.5) Pub Date : 2023-10-30 Yang Li,Guodong Deng,Ning Liang,Pingping Hu,Yan Zhang,Lili Qiao,Yingying Zhang,Jian Xie,Hui Luo,Fei Wang,Fangjie Chen,Fengjun Liu,Deguo Xu,Jiandong Zhang
Background Since the success of the PACIFIC trial, durvalumab has become the clear standard of care for many patients with stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CRT). However, the duration of immune consolidation and the efficacy and safety of different immune agents remain unclear. We conducted a systematic review of relevant studies. Methods We searched
-
Predictive value of recurrence of solid and micropapillary subtype in lung adenocarcinoma. Oncology (IF 3.5) Pub Date : 2023-10-27 Nozomu Motono,Takaki Mizoguchi,Masahito Ishikawa,Shun Iwai,Yoshihito Iijima,Hidetaka Uramoto
INTRODUCTION Although histological subtype in lung adenocarcinoma has been reported as a poor prognostic factor in several studies, its utility has not yet been revealed as an adaptation criterion of postoperative adjuvant chemotherapy. MATERIALS AND METHODS Four hundred ninety-four lung adenocarcinoma patients were enrolled in this retrospective study. A sub-analysis was performed in 420 lung adenocarcinoma
-
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study. Oncology (IF 3.5) Pub Date : 2023-10-27 Changwan Jeon,Su Hwan Kang,Sung-Bae Kim,Nam-Sun Paik,Ilkyun Lee,Seung Ki Kim,Eun Young Kim,Gil Soo Son,Young Bum Yoo,Kyung-Hee Lee,JeongSoo Shin,Sungil Ju,Harah Jang,Min Ho Park
INTRODUCTION SB3 is a trastuzumab biosimilar approved in Australia, Brazil, Canada, the European Union, the Republic of Korea, Switzerland, and the United States. This real-world study evaluated safety and effectiveness of SB3 as part of the Korean post approval safety management system. METHODS This post-marketing surveillance in Korea included patients in line with approved indications, i.e. patients
-
Viral infections and incidence of reactivations in chronic myeloid leukemia patients. Oncology (IF 3.5) Pub Date : 2023-10-17 Mahmood B Aldapt,Abdulrahman F Al-Mashdali,Khaldun Obeidat,Prem Chandra,Mohamed Yassin
Viral infections remain a significant problem for patients with chronic myeloid leukemia (CML) who undergo stem cell transplants (SCT). These infections often result from the reactivation of latent viruses. However, our understanding of the risk of viral reactivation in CML patients who have not undergone SCT is limited, and there is a scarcity of data on this topic. Tyrosine kinase inhibitors (TKI)
-
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on NLR Fluctuation and Liver Metastases. Oncology (IF 3.5) Pub Date : 2023-10-13 Kyosuke Nishio,Takuya Higashio,Kazumasa Komura,Wataru Fukuokaya,Takahiro Adachi,Yosuke Hirasawa,Takeshi Hashimoto,Atsuhiko Yoshizawa,Shuya Tsuchida,Takuya Matsuda,Takuya Tsujino,Kazuki Nishimura,Satoshi Tokushige,Keita Nakamori,Taizo Uchimoto,Shutaro Yamamoto,Kosuke Iwatani,Fumihiko Urabe,Keiichiro Mori,Takafumi Yanagisawa,Shunsuke Tsuduki,Kyoshi Takahara,Teruo Inamoto,Jun Miki,Takahiro Kimura,Yoshio
BACKGROUND AND PURPOSE It is well known that patients with objective response to pembrolizumab have a durable duration of response leading to favorable survival outcomes. We investigated the possibility of predicting the objective response with concise indicators obtained from daily clinical practice. Methods In our multi-institutional cohort, 220 platinum-refractory metastatic urothelial carcinomas
-
Outcomes and Feasibility of an Occupational Care Programme (TERRA) to Support Work Ability of Rare and Advanced Cancer Patients: A Report of 7 Cases. Oncology (IF 3.5) Pub Date : 2023-10-12 Floortje L Hosman,Sascha C A Rozemeijer,Amber D Zegers,Annemarie Becker-Commissaris,Heinz-Josef Klümpen,Maurice J D L van der Vorst,Linda Brom,Saskia F A Duijts
INTRODUCTION Advancements in the field of oncology are allowing patients to live longer, with enhanced quality of life (QoL). Accordingly, more patients with cancer are expressing the desire to return to work (RTW). Previous research has indicated that patients with a rare or advanced cancer can experience unique problems in the RTW process. METHODS This pilot study evaluated the outcomes and feasibility
-
Comprehensive analysis of the relationship between cuproptosis-related gene GCSH and prognosis, tumor microenvironment infiltration, and therapy response in endometrial cancer. Oncology (IF 3.5) Pub Date : 2023-10-12 Mengya Zhao,Haihang Nie,Peishan Qiu,Yali Yu,Haizhou Wang,Fan Wang,Jun Fang,Qiu Zhao
BACKGROUND Cuproptosis, a novel form of cell death regulated by protein lipoylation and implicated in mitochondrial metabolism. However, the impact of the cuproptosis-related gene γ-glutamylcysteine synthetase (GCSH) on endometrial cancer (EC) prognosis, tumor immune microenvironment, and therapeutic response remains to be further researched. METHODS The differential expression of GCSH between endometrial
-
Kinesin family member B18 is related to gastric mucin phenotype and contributes to gastric cancer progression by regulating epithelial-mesenchymal transition. Oncology (IF 3.5) Pub Date : 2023-10-09 Akira Ishikawa,Ryo Yasumatsu,Takafumi Fukui,Aya Kido,Narutaka Katsuya,Kazuhiro Sentani,Kazuya Kuraoka,Naohide Oue,Takahisa Suzuki,Shiro Oka,Takahiro Kotachi,Kazuaki Tanabe,Hideki Ohdan,Hassan Ashktorab,Duane Smoot,Wataru Yasui
INTRODUCTION Gastric cancer (GC) remains a common health concern worldwide and is the third leading cause of death in Japan. It can be broadly classified into gastric and intestinal mucin phenotypes using immunohistochemistry. We previously reported numerous associations of kinesin family member (KIF) genes and mucin phenotypes with GC. However, no previous studies have reported on the importance of
-
Effects of lobectomy versus sub-lobar resection on the survival in adults with stage IA left upper lobe non-small cell lung cancer: a retrospective cohort study based on the SEER database. Oncology (IF 3.5) Pub Date : 2023-10-09 Huanshun Wen,Chaoyang Liang
INTRODUCTION To compare the survival after lobectomy (LR) and sub-lobar resection (SLR) of left upper lobe (LUL) among non-small cell lung cancer (NSCLC) patients with stage IA. METHODS This retrospective cohort research analyzed public data collected by the Surveillance, Epidemiology, and End Results (SEER) database. Tumor characteristics were determined based on the International Classification of
-
Tracing the Evolution of Prostate Brachytherapy in the 20th Century. Oncology (IF 3.5) Pub Date : 2023-10-06 Michael S Schaulin,Guila Delouya,Daniel Zwahlen,Daniel Taussky
BACKGROUND Prostate brachytherapy (BT) techniques have evolved over the past century. This paper aimed to preserve our collective memory of history and the early development of its technique. We searched articles in PubMed and Google Scholar using keywords referring to authors, dates, and BT technical details, including different radioactive sources and country-specific publications. We reviewed the
-
Effects of exercise during chemo- or radiotherapy on immune markers - a systematic review. Oncology (IF 3.5) Pub Date : 2023-10-04 Anne M S De Hoop,Karin Valkenet,Jaap J Dronkers,Cyrille A M Krul,Jelle P Ruurda,Cindy Veenhof,Raymond H H Pieters
Introduction Patients with cancer receiving radio- or chemotherapy undergo many immunological stressors. Chronic regular exercise was shown to positively influence the immune system in several populations, while exercise overload may have negative effects. Exercise is currently recommended for all patients with cancer. However, knowledge regarding the effects of exercise on immune markers in patients
-
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Oncology (IF 3.5) Pub Date : 2023-09-29 Derek De-Rui Huang,Bin-Chi Liao,Wei-Hsun Hsu,Ching-Yao Yang,Yen-Ting Lin,Shang-Gin Wu,Tzu-Hsiu Tsai,Kuan-Yu Chen,Chao-Chi Ho,Wei-Yu Liao,Jin-Yuan Shih,Chong-Jen Yu,James Chih-Hsin Yang,Ann-Lii Cheng,Ying-Chun Shen
INTRODUCTION In real-world practice, most non-small cell lung cancer (NSCLC) patients receiving combined immunochemotherapy are exposed to short-course corticosteroids following immune checkpoint inhibitor (ICI) infusion to prevent chemotherapy-related adverse events. However, whether this early short-course corticosteroid use prevents immune-related adverse events (irAEs) remains unknown. METHODS
-
Extraction of interoperable data from healthcare documents by identifying Common Data Elements: an analysis of Radiation Therapy Planning CT Physician Order Entry records. Oncology (IF 3.5) Pub Date : 2023-09-20 Fabio Dennstädt,Paul Martin Putora,Michael Heuser,Eugenia Vlaskou Badra,Brigitta Gertrud Baumert,Dominic Leiser,Nikola Cihoric
INTRODUCTION Documentation as well as IT-based management of medical data is of ever-increasing relevance in modern medicine. As radiation oncology is a rather technical, data-driven discipline, standardization and data exchange are in principle possible. We examined electronic healthcare documents to extract structured information. Planning CT order entry documents were chosen for the analysis, as
-
Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab. Oncology (IF 3.5) Pub Date : 2023-09-20 Chihiro Kikugawa,Shinsuke Uchikawa,Tomokazu Kawaoka,Takahiro Kinami,Shigeki Yano,Kei Amioka,Kensuke Naruto,Yuwa Ando,Kenji Yamaoka,Masataka Tsuge,Yumi Kosaka,Kazuki Ohya,Nami Mori,Shintaro Takaki,Keiji Tsuji,Hirotaka Kouno,Hiroshi Kohno,Kei Morio,Takashi Moriya,Michihiro Nonaka,Yasuyuki Aisaka,Keiichi Masaki,Yohji Honda,Noriaki Naeshiro,Akira Hiramatsu,Hiroshi Aikata,Shiro Oka
BACKGROUND Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC.) We analyzed the outcomes of a cohort of patients with HCC and who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev)as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival. METHODS A total of 825 patients
-
Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC. Oncology (IF 3.5) Pub Date : 2023-09-19 Ou Yamaguchi,Kyoichi Kaira,Hisao Imai,Atsuto Mouri,Ayako Shiono,Yu Miura,Kosuke Hashimoto,Kunihiko Kobayashi,Hiroshi Kagamu
BACKGROUND Biomarkers for predicting the outcome of ipilimumab plus nivolumab (Nivo-Ipi) treatment in cancer patients have not been identified. Herein, we investigated the prognostic significance of inflammatory and nutritional markers in patients with advanced non-small cell lung cancer (NSCLC) receiving Nivo-Ipi. METHODS Our study retrospectively analyzed 101 patients with advanced NSCLC who received
-
Clinical implication of CDH1 mutations in genetic testing for diffuse gastric cancer patients. Oncology (IF 3.5) Pub Date : 2023-09-19 Giovanni Corso,Cristina Maria Trovato,Salvatore Petitto,Antonia Girardi,Alessandra Margherita De Scalzi,Beatrice Bianchi,Francesca Magnoni,Antonio Cioffi,Viviana Galimberti,Paolo Veronesi,Giovanni Mazzarol,Patrick Maisonneuve
INTRODUCTION The objective of this study was to re-classify published germline CDH1 variants identified in gastric cancer (GC) in accordance with the latest ClinVar definition and to correlate their pathogenicity with the established international clinical criteria for genetic testing. METHODS The relevant literature dating from 1998 to 2019 was systematically searched for data on CDH1 germline mutations
-
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis. Oncology (IF 3.5) Pub Date : 2023-09-14 Junya Kitadani,Toshiyasu Ojima,Keiji Hayata,Taro Goda,Akihiro Takeuchi,Shinta Tominaga,Naoki Fukuda,Tomoki Nakai,Hiroki Yamaue,Manabu Kawai
INTRODUCTION This study examines whether neoadjuvant docetaxel, cisplatin plus S-1 (DCS) therapy is superior to docetaxel, cisplatin plus 5-fluorouracil (DCF) therapy for resectable advanced esophageal squamous cell carcinoma (ESCC). METHODS Patients diagnosed with resectable advanced ESCC at our hospital between January 2010 and December 2019 underwent either neoadjuvant DCF therapy or DCS therapy
-
Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma. Oncology (IF 3.5) Pub Date : 2023-09-14 Reio Ueta,Hiroo Imai,Ken Saijo,Yoshifumi Kawamura,Shuto Kodera,Keigo Komine,Kota Ouchi,Yuki Kasahara,Sakura Taniguchi,Yuya Yoshida,Keiju Sasaki,Hidekazu Shirota,Masanobu Takahashi,Chikashi Ishioka
INTRODUCTION Patients with the head and neck squamous cell carcinoma (SCC) are often treated with immune checkpoint inhibitors (ICI). Recently, antibiotic intake was reported to lower the efficacy of ICIs in patients with several types of cancers. However, it is unclear if antibiotics affect the efficacy of ICIs in patients with head and neck SCC. We retrospectively assessed the influence of antibiotics
-
Impact of oophorectomy on survival and improving nutritional status in ovarian metastasis from colorectal adenocarcinoma. Oncology (IF 3.5) Pub Date : 2023-09-12 Yusuke Miyagawa,Masato Kitazawa,Shigeo Tokumaru,Satoshi Nakamura,Makoto Koyama,Yuta Yamamoto,Satoru Miyazaki,Nao Hondo,Yuji Soejima
INTRODUCTION Ovarian metastasis of colorectal cancer is known to have a poor prognosis. This study aimed to elucidate the characteristics of patients who underwent oophorectomy for ovarian metastasis from colorectal cancer. METHODS This retrospective study included 16 patients who underwent oophorectomy for colorectal cancer metastasis to the ovary from January 2004 to December 2017. Improvement in
-
Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis. Oncology (IF 3.5) Pub Date : 2023-09-12 Juraj Prejac,Tomislav Omrčen,Jasna Radić,Eduard Vrdoljak,Ana Fröbe,Stjepko Pleština
INTRODUCTION There are no recommended biomarkers to identify patients with refractory metastatic colorectal cancer (mCRC) who would benefit the most from trifluridine/tipiracil (TTP). The exploratory analysis of the RECOURSE trial revealed that patients with low tumor burden and indolent disease derive greater benefit in terms of both progression-free (PFS) and overall survival (OS). Nevertheless,
-
Mismatch repair deficiency in biliary tract cancer: prognostic implications and correlation with histology. Oncology (IF 3.5) Pub Date : 2023-09-12 Caterina Vivaldi,Virginia Genovesi,Clara Ugolini,Laura Bernardini,Andrea Casadei-Gardini,Vincenzo Formica,Francesca Salani,Giulia Orsi,Valentina Massa,Andrea Cacciato-Insilla,Miriam Caccese,Silvia Cesario,Kalliopi Andrikou,Jessica Graziani,Daniela Campani,Enrico Vasile,Gabriella Fontanini,Lorenzo Fornaro,Gianluca Masi
INTRODUCTION Mismatch repair (MMR) deficiency represents a biomarker and therapeutic target in various neoplasms, but its role in biliary tract cancers (BTCs) remains misunderstood. METHODS MMR status was retrospectively assessed using immunohistochemistry in 163-BTCs patients. We identified MMR proficiency (pMMR)/deficiency (dMMR) according to the loss of MMR proteins (MLH-1, PMS-2, MSH-2, MSH-6)
-
Radiomics Correlation to CD68+ Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma. Oncology (IF 3.5) Pub Date : 2023-09-12 Alexander Shieh,Steven Y Cen,Bino A Varghese,Darryl Hwang,Xiaomeng Lei,Ali Setayesh,Imran Siddiqi,Manju Aron,Anishka Dsouza,Inderbir S Gill,William Wallace,Vinay Duddalwar
INTRODUCTION Renal cell carcinoma (RCC) is the ninth most common cancers worldwide, with clear cell RCC (ccRCC) being the most frequent histological subtype. The tumor immune microenvironment (TIME) of ccRCC is an important factor to guide treatment, but current assessments are tissue-based, which can be time-consuming and resource-intensive. In this study, we used radiomics extracted from clinically
-
Survival outcome in early onset metastatic colorectal cancer: a multicenter matched-pair analysis. Oncology (IF 3.5) Pub Date : 2023-09-12 Bernhard Doleschal,Dora Niedersüß-Beke,Patrick Kirchweger,Andreas Petzer,Josef Thaler,Holger Rumpold
Introduction Survival of patients suffering from metastatic colorectal cancer (mCRC) has increased over the last decades. These benefits appear to be restricted to patients aged 50 and above. However, among the population aged < 50, CRC incidence and mortality rates are significantly rising. The clinical benefit of treatment in this population still is a matter of debate. We aim to compare the clinical
-
Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A biomarker for cancers. Oncology (IF 3.5) Pub Date : 2023-09-12 Leteng Yang,Jie Wei,Xiaoya Ma,Huan Zhang,Tianbo Jin
INTRODUCTION SMG5 is involved in tumor cell development and viewed as a potential target for immunotherapy. The purpose of this study was to systematically analyze the expression level, function and prognostic value of SMG5 in pan-cancers. METHODS Differential expression of SMG5 in normal and tumor tissues was analyzed using The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression database
-
Research Article Clinical significance of the TK1 specific activity in the early detection of ovarian cancer. Oncology (IF 3.5) Pub Date : 2023-09-06 Joško Osredkar,Kiran Kumar Jagarlamudi,Diana Cviič,Erik Škof,Branko Cvjetićanin,Andrej Zore,David Lukanović,Staffan Eriksson,Leon Meglič
INTRODUCTION Ovarian cancer is the eighth most common cause of cancer death in women. One of the major concerns is almost two-thirds of cases are typically diagnosed in the late stage as the symptoms are unspecific in the early stage of ovarian cancer. It is known that the combination of TK1 protein with CA 125 or HE4 showed better performance than either of them alone. That's why, the aim of the study
-
Clinicopathological characteristics of breast cancer patients with HER-2 low expression received neoadjuvant therapy. Oncology (IF 3.5) Pub Date : 2023-09-05 Shiyuan Zhang,Xiao Yu,Yuting Xiu,Kun Qiao,Cong Jiang,Yuanxi Huang
INTRODUCTION Human epidermal growth factor receptor-2 (HER2) low expression breast malignant tumors have become a research hotspot in recent years, but it is still unclear whether HER-2 low expression represents a special subtype of breast cancer. However, this molecular type requires more effective treatment regimens in the neoadjuvant therapy stage. METHODS This study enrolled breast cancer patients
-
High-mobility group box 1 overexpression predicts a poor prognosis and promotes EMT in gastric cancer by activating TLR4/NF-κB signaling. Oncology (IF 3.5) Pub Date : 2023-09-04 Jichun Ma,Mingxu Da
Objective The molecular mechanism of high-mobility group box 1(HMGB1) promoting the epithelial-mesenchymal transition (EMT) of gastric cancer(GC) has not been known well. This study aimed to explore the clinical effects of HMGB1 expression levels on the clinicopathological characteristics of patients with GC and to uncover the potential molecular mechanism by which promoting tumor progression. Methods
-
Retrospective Case-Control Study of REGEN-COV (casirivimab and imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database. Oncology (IF 3.5) Pub Date : 2023-09-04 Kazue Takemoto
INTRODUCTION Patients with cancer may be at a higher risk of experiencing severe complications from coronavirus disease 2019 (COVID-19) than are patients without cancer. This study evaluated the efficacy of REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, for treating COVID-19 in patients with cancer in the United States of America. Methods Using the MarketScan® database
-
Objective response and progression free survival contribute to prolong overall survival in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma. Oncology (IF 3.5) Pub Date : 2023-09-04 Kazuto Tajiri,Kenichiro Tsukada,Yoshiharu Tokimitsu,Yuchi Motofuji,Kengo Kawai,Nozomu Muraishi,Aiko Murayama,Yuka Hayashi,Yukihiro Shimizu,Ichiro Yasuda
INTRODUCTION Atezolizumab plus bevacizumab (Atez/Bev) is a standard treatment for unresectable hepatocellular carcinoma (HCC) due to its good anti-tumor and survival prolongation effects. Post-progression survival (PPS) has been reported to be a great contributor in the treatment with tyrosine kinase inhibitors for unrecetable HCC. This study aimed to clarify the significance of progression-free survival
-
Consumption of Sugar-sweetened Soft Drinks and Risk of Gastrointestinal Cancer: A Systematic Review and Meta-analysis of Observational Studies. Oncology (IF 3.5) Pub Date : 2023-08-31 Alfred Jatho,Seung-Kwon Myung,Jeongseon Kim,Sung-Sik Han,Sun Young Kim,Woong Ju
INTRODUCTION Previous observational studies have reported inconsistent findings on the association between consumption of sugar-sweetened soft drinks (SSSDs) and the risk of gastrointestinal (GI) cancer. This study investigated the associations between SSSD consumption and the risk of GI cancer using a systematic review and meta-analysis. METHODS Observational epidemiological studies were searched
-
The potential of trastuzumab deruxtecan as a tissue agnostic drug. Oncology (IF 3.5) Pub Date : 2023-08-31 Jan Trøst Jørgensen
BACKGROUND Many modern anticancer drugs are designed to target specific molecular alterations harbored by the cancer. If a specific drug is able to target these alterations, regardless of the organ or tissue in which the cancer originates, it will often be characterized as a tissue- or tumor agnostic drug. According to the Food and Drug Administration (FDA), a tissue agnostic drug refers to a drug
-
Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer. Oncology (IF 3.5) Pub Date : 2023-08-31 Norio Akuta,Yusuke Kawamura,Shunichiro Fujiyama,Hitomi Sezaki,Tetsuya Hosaka,Satoshi Saitoh,Mariko Kobayashi,Yasuji Arase,Kenji Ikeda,Yoshiyuki Suzuki,Hiromitsu Kumada,Fumitaka Suzuki
INTRODUCTION Personalized medicine and molecular therapies with the diagnosis of somatic genetic alterations are expected to be developed for liver cancer. Nevertheless, it is unknown whether a mutation in the telomere reverse transcriptase promoter (TERT C228T) in serum cfDNA might be useful for making prognostic predictions after surgical resection for primary liver cancer. METHODS This cohort study
-
Analysis of risk factors for recurrence after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer: 2-year follow-up outcomes. Oncology (IF 3.5) Pub Date : 2023-08-30 Hecheng Li,Li Wang,Hongliang Li,Peng Zheng,Zhaolun Li,Li Xue,Zhenlong Wang,Delai Fu,Qi Chen,Qidong Luo,Tie Chong,Ziming Wang
INTRODUCTION The aim was to investigate the risk factors for recurrence after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC) and to provide a basis for clinical prevention of recurrence of NMIBC. METHODS From January 2012 to December 2020, 592 patients with NMIBC who underwent TURBT attending the Second Affiliated Hospital of Xi'an Jiaotong
-
Survival Benefit from Multimodal Treatment for Patients with Atypical Teratoid Rhabdoid Tumor in a Surveillance, Epidemiology and End Result Database Analysis. Oncology (IF 3.5) Pub Date : 2023-08-25 Abhishek S Bhutada,Srijan Adhikari,Joshua A Cuoco,Cara M Rogers,Eric A Marvin
Introduction Atypical teratoid rhabdoid tumor (ATRT) is among the most aggressive central nervous system malignancies. Although rare, this tumor typically afflicts young children and results in mortality within months. Here, we aim to determine key clinical features and treatment options that impact survival of patients with ATRT. Methods From the years 2000 to 2018, 363 patients with ATRT were identified
-
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology (IF 3.5) Pub Date : 2023-08-23 Shadi Chamseddine,Yehia I Mohamed,Sunyoung S Lee,James C Yao,Zishuo Ian Hu,Hop S Tran Cao,Lianchun Xiao,Ryan Sun,Jeffrey S Morris,Rikita I Hatia,Manal Hassan,Dan G Duda,Maria Diab,Amr Mohamed,Ahmed Nassar,Saumil Datar,Hesham M Amin,Ahmed Omar Kaseb
INTRODUCTION Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall
-
Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance. Oncology (IF 3.5) Pub Date : 2023-08-18 Yuko Kanbayashi,Asuka Kojima,Haruka Wakabayashi,Tadashi Shimizu,Mayako Uchida
BACKGROUND Cardiac adverse events (CAEs) have become a concern as serious adverse events of nilotinib administration. No reports have described the incidence of CAEs associated with nilotinib in Japanese patients. OBJECTIVES Thus, we conducted this study to evaluate the risk of nilotinib-induced CAEs, time to onset, incidence rates, and post hoc outcomes using the Japanese Adverse Drug Event Report
-
Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer. Oncology (IF 3.5) Pub Date : 2023-08-18 Chrystal A Landry,Julia Blanter,Meng Ru,Julie Fasano,Paula Klein,Theresa Shao,Aarti Bhardwaj,Amy Tiersten
INTRODUCTION The release of tumor-associated antigens with cytotoxic chemotherapy treatment may enhance the response to immune checkpoint blockade. Eribulin is a microtubule inhibitor with proven overall survival (OS) benefit in metastatic breast cancer (MBC), which may also enhance intratumoral vascular remodeling. Durvalumab, a humanized monoclonal antibody, targets the programmed cell death ligand-1
-
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel. Oncology (IF 3.5) Pub Date : 2023-08-18 Fuyumi Nishihara-Kato,Hisao Imai,Takeshi Tsuda,Satoshi Wasamoto,Yoshiaki Nagai,Takayuki Kishikawa,Yosuke Miura,Akihiro Ono,Yutaka Yamada,Ken Masubuchi,Takashi Osaki,Junichi Nakagawa,Yukihiro Umeda,Hiroyuki Minemura,Yuki Kozu,Hirokazu Taniguchi,Hiromitsu Ohta,Kyoichi Kaira,Hiroshi Kagamu
INTRODUCTION Pembrolizumab (Pemb) therapy in conjunction with carboplatin and paclitaxel (PTX)/nab-PTX has been efficacious in treating non-small-cell lung cancer (NSCLC). However, the response predictors of this combination therapy (Pemb-combination) remain undetermined. We aimed to evaluate whether Glasgow prognostic score (GPS), neutrophil-to-lymphocyte ratio (NLR), body mass index (BMI), platelet-to-lymphocyte
-
Disparate Outcomes, Biologic and Therapeutic Differences in Pediatric versus Adult Patients with Ewing Sarcoma. Oncology (IF 3.5) Pub Date : 2023-08-18 Victoria Wytiaz,Eric Schwartz,John D Rice,Lili Zhao,Rama Jasty,Scott Schuetze,Rashmi Chugh
INTRODUCTION Ewing Sarcoma (ES) is a small blue round cell sarcoma affecting a wide age spectrum. Clinical advances predominately stem from pediatric research consortia clinical trials. In most series, adults have poorer outcomes when compared to children. The aim of this study was to perform a detailed evaluation of factors potentially accounting for this difference. METHODS A single institution retrospective
-
The efficiency of autologous hematopoietic stem cell transplantation for follicular lymphoma: a systematic review and meta-analysis. Oncology (IF 3.5) Pub Date : 2023-08-18 Xinsheng Liu,Yaxin Zheng,Hongtao Li,Meiyi Wang,M James You,Chen Tian
Background The effect of autologous hematopoietic stem cell transplantation (auto-HSCT) versus conventional chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the survival of patients with advanced follicular lymphoma (FL) is uncertain. Objectives To elucidate this, FL and HSCT were used as keywords to search in PubMed, Embase, Web of Science, and Cochrane Library databases
-
Evaluation of time to onset and outcome of lung adverse events related to pembrolizumab using marketing surveillance. Oncology (IF 3.5) Pub Date : 2023-08-17 Yuko Kanbayashi,Momoko Kobayashi,Miku Anzai,Tadashi Shimizu,Mayako Uchida
Background Pembrolizumab has been widely used in patients since its release, but detailed information on lung-specific adverse events (AEs) from post-marketing monitoring has not been reported. Objectives This study was undertaken to determine the risk of pembrolizumab-induced lung AEs, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Report database. Method We analyzed data
-
Adverse metabolic effects on glucose in patients receiving anamorelin using a Japanese claims database. Oncology (IF 3.5) Pub Date : 2023-08-14 Hiroaki Ohta,Takeshi Horii,Takeo Yasu
BACKGROUND Anamorelin is the first drug approved for the treatment of cancer cachexia, a debilitating condition characterized by weight loss, anorexia, and muscle mass depletion. Cachexia negatively affects a patient's quality of life, survival, and response to chemotherapy. Studies describing anamorelin use are currently limited to a small number of pancreatic cancer cases. OBJECTIVES We aimed to
-
Comparing COVID-19 Response Behaviors between a Cancer Patient Sample and a Population-Based Cancer-Free Sample in a Rural Midwestern State. Oncology (IF 3.5) Pub Date : 2023-08-14 Breanna B Greteman,Crystal J Garcia-Auguste,Amanda R Kahl,Brian M Gryzlak,Elizabeth A Chrischilles,Mary E Charlton,Sarah H Nash
Introduction The COVID-19 pandemic caused an increase in fear, anxiety, and depressive symptoms globally. For populations at increased risk for adverse outcomes due to illness, such as cancer patients, these worries may have been exacerbated. Understanding how the pandemic impacted cancer patients will inform better preparation for future events that cause disturbances to cancer care delivery. Methods
-
Correlation of baseline tumor burden with clinical outcome in melanoma patients treated with ipilimumab. Oncology (IF 3.5) Pub Date : 2023-08-14 Daniela Angelova-Toshkina,Benjamin Weide,Lutz F Tietze,Michelle Hebst,Julia K Tietze
INTRODUCTION Tumor burden is a frequently mentioned parameter; however, a commonly accepted definition is still lacking. METHODS In this double center prospective and retrospective study 76 patients with unresectable stage III or stage IV melanoma treated with ipilimumab were included. We defined the baseline tumor burden (BTB) as the global sum of all metastases' longest diameters before treatment
-
Current status and future direction of albumin-bilirubin in hepatocellular carcinoma: a bibliometric analysis. Oncology (IF 3.5) Pub Date : 2023-08-14 Youao Zhang,Huiling Yang,Qi Zhou,Ke Chen,Jieyan Wang,Hui Liang
INTRODUCTION Hepatocellular carcinoma (HCC) is a common malignant tumor, so we need a convenient and objective way to diagnose and treat HCC. We discuss the current situation, progress, hotspots and existing problems of albumin-bilirubin (ALBI) in HCC, which can provide new ideas for the prevention, diagnosis and treatment of HCC. METHODS We adopt Excel 2019 software and visual analysis tools based
-
Exploration of extracellular vesicle long non-coding RNAs in serum of patients with cervical cancer. Oncology (IF 3.5) Pub Date : 2023-08-12 Piyatida Molika,Rassanee Bissanum,Komwit Surachat,Kovit Pattanapanyasat,Jitti Hanprasertpong,Wilaiwan Chotigeat,Raphatphorn Navakanitworakul
Cervical cancer (CC) is the fourth most common cancer type and a leading cause of cancer-related deaths in women worldwide. Its underlying molecular mechanisms are unclear. Cancer cell-derived extracellular vesicles (EVs) are involved in cancer development and progression by delivering regulatory factors, including microRNAs and long non-coding RNAs (lncRNAs). Here, we identified the EV lncRNA expression
-
[18F] FDG PET/MR-defined EMVI predicts distant metastasis and reflects strong tumor invasiveness in rectal cancer. Oncology (IF 3.5) Pub Date : 2023-08-10 Takayuki Matsunaka,Takanori Goi,Hidetaka Kurebayashi,Mitsuhiro Morikawa,Hidehiko Okazawa,Tetsuya Tsujikawa
INTRODUCTION Extramural vascular invasion in patients with rectal cancer is a poor prognostic factor associated with distant metastasis; thus, accurate preoperative diagnosis is important. However, the accurate detection of extramural vascular invasion using magnetic resonance imaging is difficult, and an improved diagnostic modality is required. In addition, the factors involved in the formation of
-
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings. Oncology (IF 3.5) Pub Date : 2023-08-08 Hideko Ohama,Atsushi Hiraoka,Toshifumi Tada,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Satoshi Yasuda,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki,Noritomo Shimada,Kazuhito Kawata,Atsushi Naganuma,Hisashi Kosaka,Tomomitsu Matono,Hiroshi Shibata
INTRODUCTION Systemic treatment is generally recommended for Child-Pugh (CP) A status patients with an unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate differences regarding therapeutic efficacy between lenvatinib (LEN), a multi-molecular target agent, and atezolizumab plus bevacizumab (Atez/Bev), a newly developed immune-combined therapeutic regimen for CP-B patients affected
-
Overexpression of SOX2 Gene by Histone Modifications: SOX2 Enhances Human Prostate and Breast Cancer Progression by Prevention of Apoptosis and Enhancing Cell Proliferation. Oncology (IF 3.5) Pub Date : 2023-08-04 Swayamsiddha Kar,Niharika,Ankan Roy,Samir Kumar Patra
INTRODUCTION SOX2 plays a crucial role in tumor development, cancer stem cell maintenance, and cancer progression. Mechanisms of SOX2 gene regulation in human breast and prostate cancers are not established yet. METHODS SOX2 expression in prostate and breast cancer tissues and cell lines was determined by qRT-PCR, Western blot, and immunochemistry, followed by the investigation of pro-tumorigenic properties